Press

MindMed Announces Business Update and Anticipated Milestones for 2024

Jan 11 • 7 min read

— Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) position for multiple data readouts and catalysts throughout 2024 including initiation of Phase 3 clinical program — — Proof-of-Concept study evaluating repeated sub-perceptual dose (20 μg) of lysergide in adults with Attention-Deficit/Hyperactivity Disorder (ADHD) did not…

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

Jan 11 • 2 min read

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-547495 entitled: Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF). The Company was previously…

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

Jan 11 • 3 min read

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has received approval to move its PharmAla-1 (P1) molecule through the US Patent and Trademark Office (USPTO) Patent Prosecution Highway…

Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement

Jan 11 • 5 min read

Clearmind Medicine Inc. (NASDAQ: CMND) (the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of Common Shares and pre-funded warrants in a registered direct offering. In a…

BRAINWeek 2024 to Feature Three Nationally-Acclaimed, Energizing Keynote Speakers Who Will Address the Field’s Most Relevant Topics on Brain Health.

Jan 11 • 2 min read

BRAINWeek, a respected leader in the continuing medical education space, announces its lineup of nationally recognized, keynote speakers. This dynamic group is poised to address current topics using insight from their successful practices, extensive writing and industry knowledge. Introducing our 2024 Keynotes: About BRAINWeek 2024 BRAINWeek 2024 Conference—Gaps in Brain Health: Putting Together the Pieces is…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436